Multiple Over-1-Billion-Yuan API Projects Launched in 2026 with Recent IPO Filings

　　【Pharmaceutical Network Industry Dynamics】Active Pharmaceutical IngredientsThe API industry is one of the core directions of China's new pharmaceutical manufacturing. APIs play a significant role in the development of the pharmaceutical industry. In recent years, with the continuous acceleration of the pharmaceutical industry, China's API market has been continuously expanding, and the industry's concentration has also improved to a certain extent. Notably, as the API market benefits from the sustained positive development of the pharmaceutical industry and experiences rapid growth, a large number of API companies are expanding their production capacity to further meet the demand for APIs in the pharmaceutical market.
 

Recently, the construction of the polypeptide active pharmaceutical ingredient (API) project by SPACE PEPTIDES PHARMACEUTICAL (TAIZHOU) CO., LTD., with a total investment of 1.03 billion yuan, has commenced in Taixing Economic Development Zone. According to reports, the polypeptide API project is invested and constructed by Space Peptides, with a total investment of 1.03 billion yuan, covering an area of 120 mu. The project will produce 1,100 kilograms of high value-added polypeptide APIs annually, spanning treatment areas such as diabetes, anticoagulation, and varicose vein therapy.
 

According to the plan, the project is scheduled for completion in December 2022. Once operational, it is expected to generate an annual sales revenue of 3 billion yuan and tax revenue of 420 million yuan. Upon completion, industry experts anticipate that it will achieve the industrial production of high-quality peptide active pharmaceutical ingredients (APIs), driving the pharmaceutical industry chain of Taixing Economic Development Zone toward the high end of the value chain.
 

In October, Hubei Hengdi Pharmaceutical Co., Ltd. announced its plan to go public on the ChiNext Board of the Shenzhen Stock Exchange. It intends to issue no more than 60 million shares and aims to raise 1.19 billion yuan. The funds will be allocated to several projects: a 5,000-ton ibuprofen raw material production project per year, a 1,200-ton raw material production project per year, a 12-ton anti-cancer raw material production project per year, and a working capital replenishment project. Specifically, 570 million yuan will be used for the 5,000-ton ibuprofen raw material project, 290 million yuan for the 1,200-ton raw material project, 175 million yuan for the 12-ton anti-cancer raw material project, and 150 million yuan for the working capital replenishment project.
 

The prospectus shows that Hengdi Pharmaceutical Co., Ltd. is a company mainly engaged in the research, development, production, and sales of chemical active pharmaceutical ingredients (APIs) and formulation products. Currently, it has formed a product system with non-steroidal anti-inflammatory APIs as its core, complemented by specialty APIs such as cardiovascular and anti-tumor categories.
 

In September, Space Peptides GMP API andIntermediateThe production base project was signed in Lujiang County, Hefei City, Anhui Province. The total investment of the project is about 8 billion yuan, covering an area of approximately 800 mu. The project will be constructed in three phases, and upon completion of all three phases, it is expected to achieve an annual output value of about 12 billion yuan.
 

Public information shows that Leapwing Pharma is a company specializing in industrial outsourcing services for the innovative pharmaceutical industry. Its service scope covers process transformation from laboratory to industrialization of innovative drugs, including process R&D, process optimization, pilot testing, and scale production from pre-clinical to post-approval stages. Currently, it has established branches in Beijing, Tianjin, Taizhou, Cangzhou, and the United States, including management centers, pilot R&D platforms, non-GMP pilot R&D services, production workshops, multi-functional cGMP production workshops, as well as overseas branches.
 

Overall, the API industry is currently facing excellent development opportunities. Many API companies in China have already started forward-looking layouts and are continuously expanding their production capacity. Notably, in addition to this, the industry has also proposed that, in order to better promote the development of the API sector, API companies need to further strengthen R&D investment in related fields, constantly enrich their product pipelines for higher growth, and enhance the company's core competitiveness through medium- and long-term strategies to expand market share, driving stable growth in sales revenue and profits.